STOCK TITAN

CYAD - CYAD STOCK NEWS

Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.

CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.

Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.

Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.

Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.

News
Rhea-AI Summary
Celyad Oncology (CYAD) announces CEO Georges Rawadi's resignation for personal reasons, effective December 1, 2023. Co-founder Michel Lussier takes over as interim CEO. The company aims to maximize the impact of its CAR T-cell therapies and redefine the future of CAR T-cell treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Celyad Oncology SA (Euronext: CYAD) received a transparency notification from Tolefi SA and related persons indicating they have jointly crossed passively below the 15% threshold, holding 6,568,978 shares, or 14.997% of the voting rights of the Company as of November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Celyad Oncology SA (CYAD) received a notification of transparency indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 50%, holding 22,858,654 shares i.e. 52.19% of Celyad Oncology’s voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Celyad Oncology (CYAD) Announces Capital Increase and New Share Issuance to Affiliate of Fortress Investment Group, Resulting in Share Capital of 88,378,224.25 EUR and 41,428,572 Shares. The company has published this information in compliance with Belgian disclosure regulations, with the total number of diluted shares now at 44,467,443.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Celyad Oncology (Euronext: CYAD) reports financial results for Q3 2023, including a private placement commitment of EUR 9.8m. The company presented data on its multiplex shRNA approach and NKG2D-based multi-specific CAR T-cell platform at international conferences. The company's cash and cash equivalents are projected to fund operating expenses into Q2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Celyad Oncology announces termination of its American Depository Receipt program, ADS holders can surrender their ADSs and receive underlying ordinary shares before October 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Celyad Oncology received a rectified notification of transparency indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, now holds 29.99% of the company's shares and 27.53% voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Celyad Oncology received a transparency notification that Tolefi SA and related persons crossed the 20% threshold, holding 22.74% of the voting rights of the Company as of September 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group, has acquired 29.99% of Celyad Oncology's shares and 27.53% voting rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has crossed the threshold of 25%, holding 29.99% of Celyad Oncology's shares and 27.53% voting rights as of August 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
CYAD

Nasdaq:CYAD

CYAD Rankings

CYAD Stock Data

14.24M
13.58M
0.05%
29.15%
0.58%
Biotechnology
Healthcare
Link
Belgium
Mont-Saint-Guibert